PIERIS PHARMACEUTICALS, INC. (PIRS) [Rocket]

Overview

PIERIS PHARMACEUTICALS, INC. (PIRS)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/17/2023	SC 13D/A	BIOTECHNOLOGY VALUE FUND L P reports a 20.8% stake in Pieris Pharmaceuticals, Inc.
08/10/2023	S-8	Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023	10-Q	Quarterly Report for the period ended June 30, 2023
07/18/2023	8-K	Quarterly results
07/13/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/30/2023	4	KIRITSY CHRISTOPHER P (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	25.9	31.4	29.3	46.3	27.2	25.3	5.8	2.9
Revenue growth	-17.6%	7.1%	-36.6%	69.8%	7.8%	333.5%	98.9%	-45.4%
Cost of goods sold	0.0	0.0	0.0	0.0	-1.9	0.0	0.0	0.0
Gross profit	25.9	31.4	29.3	46.3	29.1	25.3	5.8	2.9
Gross margin	100.0%	100.0%	100.0%	100.0%	106.8%	100.0%	100.0%	100.0%
Selling, general and administrative
Research and development	53.0	66.7	46.5	55.0	41.5	22.3	19.7	8.2
General and administrative	16.4	16.6	16.7	18.4	18.4	17.6	8.9	8.4
EBIT	-43.5	-51.8	-33.9	-27.2	-30.8	-14.6	-22.8	-13.7
EBIT margin	-167.8%	-165.0%	-115.7%	-58.7%	-113.1%	-57.7%	-390.3%	-466.6%
Pre-tax income	-33.3	-45.7	-37.1	-25.5	-27.1	-16.5	-22.6	-13.9
Income taxes	0.0	0.0	0.2	0.0	-0.3	1.1	0.2	0.2
Tax rate	0.0%	0.0%		0.0%	1.2%
Net income	-33.3	-45.7	-37.2	-28.3	-26.8	-17.6	-22.8	-14.1
Net margin	-128.6%	-145.5%	-126.9%	-61.1%	-98.2%	-69.8%	-391.0%	-479.5%

Diluted EPS	($0.45)	($0.71)	($0.68)	($0.56)	($0.50)	($0.40)	($0.55)	($0.41)
Shares outstanding (diluted)	74.2	64.5	54.5	50.6	53.1	43.9	41.7	34.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.